-
Story
Innovating for America: How Our New RLT Manufacturing Site Can Help Ensure Continued On Time Delivery to Patients Now and in Future -
Media Release
Novartis data underscore pioneering scientific innovation in hematology and oncology at ASH and SABCS
-
Media Release
Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)
-
Story
Changing Lives: Inside the Novartis Corporate Teen Mentoring Program -
Media Release
New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline
-
Media Release
Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials
-
Media Release
Novartis showcases significant immunology advancements at ACR congress with new data in complex autoimmune diseases
-
Story
Underserved but Not Out of Reach: 3 Ways to Bridge Care Gaps in Communities to Improve Advanced Prostate Cancer -
Media Release
Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)
-
Media Release
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
-
Media Release
Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population
-
Media Release
Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)